{"id":"W4389029721","doi":"10.1093/ofid/ofad500.1532","title":"1699. Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients","year":2023,"lang":"en","type":"article","venue":"Open Forum Infectious Diseases","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal","funders":"Janssen Biotech; Genentech; National Institutes of Health; Basilea Pharmaceutica; Astellas Pharma; Sanofi; Nabriva Therapeutics; Moderna; Sanofi Pasteur; Amplyx; KU Leuven; Jazz Pharmaceuticals; Gilead Sciences; Pfizer; Melinta Therapeutics; Astellas Pharma Global Development; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Aspergillosis; Adverse effect; Mucormycosis; Incidence (geometry); Case fatality rate; Population; Neutropenia; Internal medicine; Surgery; Pediatrics; Toxicity; Epidemiology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001256864,0.0001982435,0.000636143,0.0001595092,0.0001457689,0.00002124798,0.0001365155,0.00006379495,0.0000637828],"category_scores_gemma":[0.00123662,0.0001149637,0.000205432,0.0004899701,0.0001222538,0.0001540405,0.0001195876,0.00003990831,0.000006341191],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001312537,"about_ca_system_score_gemma":0.0003446833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008767552,"about_ca_topic_score_gemma":0.009704825,"domain_scores_codex":[0.9986702,0.00005041783,0.0004910405,0.000307651,0.0001970205,0.0002836785],"domain_scores_gemma":[0.9970616,0.002069806,0.0002129285,0.0003419628,0.0002032172,0.0001104949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001989941,0.001254929,0.9922724,0.0003262703,0.0002076583,0.000005181051,0.0002677806,0.0000111266,0.00002070595,0.0001325473,0.0004791263,0.003032325],"study_design_scores_gemma":[0.005273862,0.002196901,0.9900617,0.00006151196,0.00049932,4.988507e-7,0.00075776,0.00001457326,0.0005861145,0.0002560187,0.0001727871,0.0001189337],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954163,0.000430356,0.00000573825,0.0004208791,0.0001062306,0.002515517,0.0006517596,0.00002247694,0.000430698],"genre_scores_gemma":[0.9882199,0.0107299,0.00001207592,0.0001332117,0.00001763414,0.0002642035,0.0001141092,0.00002156984,0.0004874236],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01029954,"threshold_uncertainty_score":0.5415521,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02166402858186709,"score_gpt":0.3032928494492307,"score_spread":0.2816288208673636,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}